FTC, State AGs Say Humira Judge Botched Actavis Reading

Law360 (October 14, 2020, 4:39 PM EDT) -- The Federal Trade Commission and a group of state attorneys general are urging the Seventh Circuit to address mistakes they say a district court made in tossing a lawsuit claiming AbbVie built an anti-competitive "patent thicket" around its blockbuster immunosuppressant Humira to keep cheaper biosimilars from the market.

In separate amicus briefs on Tuesday, the FTC and the enforcers from 20 states took aim at U.S. District Judge Manish Shah's application of the U.S. Supreme Court's landmark decision in FTC v. Actavis Inc., which said so-called pay-for-delay or reverse payment settlements staving off generic competition could be anti-competitive in some circumstances....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!